By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad Pharmaceuticals, Inc.
Symbol: ARIA

Company News
Ariad Pharmaceuticals, Inc. (ARIA) And Specialised Therapeutics Australia Announce Approval Of Iclusig (Ponatinib) In Australia 11/24/2014 9:38:04 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Iclusig Data Presentations At Annual American Society of Hematology Meeting 11/6/2014 11:39:02 AM
Ariad Pharmaceuticals, Inc. (ARIA) Reports Third Quarter 2014 Financial Results And Development Progress 11/5/2014 10:07:28 AM
Ariad Pharmaceuticals, Inc. (ARIA) To Present At The Stifel 2014 Healthcare Conference 11/4/2014 10:01:44 AM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Adoption of Final Opinion For Iclusig By Committee For Medicinal Products For Human Use In Europe 10/24/2014 9:42:07 AM
Ariad Pharmaceuticals, Inc. (ARIA) To Webcast Conference Call On Third Quarter 2014 Financial Results 10/15/2014 9:10:34 AM
Ariad Pharmaceuticals, Inc. (ARIA)’s Harvey Berger Says He’s "Absolutely" Secure In His Role As CEO 10/13/2014 6:12:39 AM
PRAC Decision On Leukemia Drug Good News For Ariad Pharmaceuticals, Inc. (ARIA), Says Analyst 10/10/2014 3:24:40 PM
Ariad Pharmaceuticals, Inc. (ARIA) Announces Recommendation For Iclusig By The Pharmacovigilance Risk Assessment Committee Of The European Medicines Agency 10/10/2014 8:04:25 AM
Ariad Pharmaceuticals, Inc. (ARIA), Bellicum Pharmaceuticals, Inc. Revise Pact; Ariad Will Receive $50 Million In Three Installments 10/6/2014 6:02:39 AM